A test of the role of α5 integrin/fibronectin interactions in tumorigenesis

Cancer Research

Volumn 58, Issue 4, 1998, Pages 848-853

  Taverna, Daniela ^a   Ullman Culleré, Mollie ^a   Rayburn, Helen ^a   Bronson, Roderick T ^b   Hynes, Richard O ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; FIBRONECTIN; INTEGRIN; PROTEIN P53; FIBRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CHIMERA; GENOTYPE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; ANIMAL; DISEASE COURSE; GENETICS; HETEROZYGOSITY LOSS; HETEROZYGOTE; MOUSE MUTANT; NEOPLASM; PHYSIOLOGY;

ANIMALS; DISEASE PROGRESSION; FIBRONECTINS; GENES, P53; HETEROZYGOTE; LOSS OF HETEROZYGOSITY; MICE; MICE, KNOCKOUT; NEOPLASMS; RECEPTORS, FIBRONECTIN;

EID: 0032518992     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Adams, J. C., and Watt, F. M. Regulation of development and differentiation by the extracellular matrix. Development (Camb.), 117: 1183-1198, 1993.
2. Hynes, R. O. Fibronectin. New York: Springer-Verlag, 1990.
3. Hynes, R. O. Integrins: versatility, modulation and signaling in cell adhesion. Cell, 69: 11-25, 1992.
4. Ruoslahti, E. Integrins. J. Clin. Invest., 87: 1-5, 1991.
5. Hynes, R. O., and Lander, A. D. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell, 68: 303-322, 1992.
6. Giancotti, F. G., and Mainiero, F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim. Biophys. Acta, 1198: 47-64, 1994.
7. Haas, T. A., and Plow, E. F. Integrin-ligand interactions: a year in review. Curr. Opin. Cell Biol., 6: 656-662, 1994.
8. Ruoslahti, E. Integrin signaling and matrix assembly. Tumor Biol., 17: 117-124, 1996.
9. Juliano, R. L., and Haskill, S. Signal transduction from the extracellular matrix. J. Cell. Biol., 120: 577-585, 1993.
10. Clark, E. A., and Brugge, J. S. Integrins and signal transduction pathways: the road taken. Science (Washington DC), 268: 233-239, 1995.
11. Schwartz, M. A., Schaller, M. D., and Ginsberg, M. H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell. Dev. Biol., 11: 549-599, 1995.
12. Takeichi, M. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol., 5: 806-811, 1993.
13. Burchill, S. A. The tumor suppressor APC gene product is associated with cell adhesion. BioEssays, 16: 225-227, 1994.
14. Peifer, M. β-Catenin as oncogene: the smoking gun. Science (Washington DC), 275: 1752-1753, 1997.
15. Gusella, J. F., Ramesh, V., MacCollin, M., and Jacoby, L. B. Neurofibromatosis 2: loss of Merlin's protective spell. Curr. Opin. Genet. Dev., 6: 87-92, 1996.
16. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65: 13-24, 1991.
17. Wielanga, V. J. M., Heider, K. H., Offerhaus, G. J. A., Adolf, G. R., van der Berg, F. M., Ponta, H., Herrlich, P., and Pals, S. T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res., 53: 4754-4756, 1993.
18. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G., Ponta, H., and Herrlich, P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345: 615-619, 1995.
19. Akiyama, S. K., Olden, K., and Yamada, K. M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev., 14: 173-189, 1995.
20. Hynes, R. O., and Plantefaber, L. C. Integrin receptors for extracellular matrix and their involvement in oncogenic transformation. In: J. Brugge, T. Curran, E. Harlow, and F. McCormick (eds.), Origins of Human Cancer: A Comprehensive Review. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1991.
21. Zutter, M. M., Krigman, H. R., and Santoro, S. A. Altered integrin expression in adenocarcinoma of the breast. Am. J. Pathol., 142: 1439-1448, 1993.
22. 1 integrin abrogates the malignant phenotype of breast carcinomas cells. Proc. Natl. Acad. Sci. USA, 92: 7411-7415, 1995.
23. Plantefaber, L. C., and Hynes, R. O. Changes in integrin receptors on oncogenically transformed cells. Cell, 56: 281-290, 1989.
24. 1 fibronectin receptor suppresses the transformed phenotype of Chinese hamster ovary cells. Cell, 60: 849-859, 1990.
25. 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol. Biol. Cell, 6: 725-740, 1995.
26. Dedhar, S., Argraves, W. S., Susuki, S., Ruoslahti, E., and Pierschbacher, M. D. Human osteosarcoma cells resistant to detachment by an Arg-Gly-Asp-containing peptide overproduce the fibronectin receptor. J. Cell Biol., 105: 1175-1182, 1987.
27. Dedhar, S., Mitchell, M. D., and Pierschbacher, M. D. The osteoblast-like differentiation of a variant of MG-63 osteosarcoma cell line correlated with altered adhesive properties. Connect. Tissue Res., 20: 49-61, 1989.
28. Symington, B. E. Fibronectin receptor overexpression and loss of transformed phenotype in a stable variant of the K562 cell line. Cell Regul., 1: 637-648, 1990.
29. Weinel, R. J., Rosendahl, A., Neumann, K., Chaloupka, B., Erd, D., Rothmund, M., and Santoso, S. Expression and function of VLA α2, α3, α5 and α6 integrin receptors in pancreatic carcinoma. Int. J. Cancer, 52: 827-833, 1992.
30. Tennenbaum, T., Yuspa, S. H., Grover, A., Castronovo, V., Sobel, M. E., Yamada, Y., and DeLuca, L. M. Extracellular matrix receptors and mouse skin carcinogenesis: altered expression linked to appearance of early markers of tumor progression. Cancer Res., 52: 2966-2976, 1992.
31. Stallmach, A., von Lampe, B. V., Matthes, H., Bornhoft, G., and Riecken, E. O. Diminished expression of integrin adhesion molecules on human colonie epithelial cells during the benign to malignant tumor transformation. Gut, 33: 342-346, 1992.
32. 3 subunit with tumor progression. Cancer Res., 50: 6757-6764, 1990.
33. Danen, E. H., Jansen, K. F., Van Kraats, A. A., Cornelissen, I. M., Ruiter, D. J., and Van Muijen, G. N. αv integrin in human melanoma: gain of αvβ3 and loss of αvβ5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer, 61: 491-496, 1995.
34. Bartolazzi, A., Cerboni, C., Nicotra, M. R., Mottolese, M., Bigotti, A., and Natali, P. G. Transformation and tumor progression are frequently associated with expression of the α3/β1 heterodimers in solid tumors. Int. J. Cancer, 58: 488-491, 1994.
35. Van Waes, C., and Carey TE. Overexpression of the A9 antigen α6β4 in head and neck cancer. Otolaryngol. Clin. North Am., 25: 1117-1139, 1992.
36. Liebert, M., Wedemeyer, G., Stein, J. A., Washington, R. W., Jr., Van Waes, C., Carey, T. E., and Grossman, H. B. The monoclonal antibody BQ16 identifies the α6β4 integrin on bladder cancer. Hybridoma, 12: 67-80, 1993.
37. Costantini, R. M., Falcioni, R., Battista, P., Zupi, G., Kennel, S. J., Colasante, A., Venturo, I., Curio, C., and Sacchi, A. Integrin α6β4 expression in human lung cancer as monitored by specific monoclonal antibodies. Cancer Res., 50: 6107-6112, 1990.
38. Varner, J. A., and Cheresh, D. A. Review: integrins and cancer. Curr. Opin. Cell Biol., 8: 724-730, 1996.
39. George, E. L., Georges-Labouesse, E. N., Patel-King, R. S., Rayburn, H., and Hynes, R. O. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development, 119: 1079-1091, 1993.
40. Yang, J. T., Raybum, H., and Hynes, R. O. Embryonic mesodermal defects in α5 integrin-deficient mice. Development, 119: 1093-1105, 1993.
41. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
42. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
43. Mortensen, R. M., Conner, D. A., Chao, S., Geisterfer-Lowrance, A. A. T., and Saidman, J. G. Production of homozygous mutant ES cells with a single targeting construct. Mol. Cell. Biol., 12: 2391-2395, 1992.
44. Stewart, C. L. Production of chimeras between embryonic stem cells and embryos. Methods Enzymol., 225: 823-854, 1993.
45. Bradley, A. Production and analysis of chimeric mice. In: E. J. Robertson (ed.), Teratocarcinomas and Embryonic Stem Cell: A Practical Approach, pp. 113-151. Oxford, United Kingdom: IRL Press, 1987.
46. Church, G. M., and Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA, 81: 1991-1995, 1984.
47. Donehower, L. A., Harvey, M., Slage, B. L., McArthur, M. J., Montgomery, C. A. Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
48. Greenblatt, M. S., Bennet, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
49. Harvey, M., McArthur, M. J., Montgomery, C. A., Jr., Bradley, A., and Donehower, L. A. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J., 73: 938-943, 1993.
50. Lee, E. Y. H. P., Chang, C. Y., Hu, N., Wang, Y. C. J., Lai, C. C., Herrup, K., Lee, W. H., and Bradley, A. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature (Lond.), 359: 288-294, 1992.
51. Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., and Weinberg, R. A. Effect of an Rb mutation in the mouse. Nature (Lond.), 359: 295-300, 1992.
52. Williams, B. O., Schmitt, E. M., Remington, L., Bronson, R. T., Albert, D. M., Weinberg, R. A., and Jacks, T. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J., 13: 4251-4259, 1994.
53. Maandag, E. C. R., van der Valk, M., Vlaar, M., Feltkamp, C., O'Brien, J., van Roon, M., van der Lugt, N., Berns, A., and te Riele, H. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J., 13: 4260-4268, 1994.